Navigation Links
GenoLogics Announces Bioinformatics Partnership with Illumina

GenoLogics Announces Bioinformatics Partnership with Illumina

BEYOND GENOME CONFERENCE, San Francisco, CA, June 21, 2007 -GenoLogics, a leading developer of lab and data management software solutions for life sciences research, today announced that it has penned an agreement with Illumina, Inc. to become a technology partner and participant in IlluminaConnect, a bioinformatics software program established by Illumina to advance data integration and analysis among the life science community.

GenoLogics will build integrations into Geneus that support Illumina?s BeadArray technology platforms and software for both gene expression and genotyping applications. Geneus includes science-specific modules that are purposed for multiple genomics application areas, and is built on an enterprise laboratory information management system (LIMS) platform designed for scientific lab and data management.

Omoshile Clement, Ph.D., Senior Product Manager, Platforms at Illumina commented, "We are very happy to welcome GenoLogics as a new IlluminaConnect partner, and we look forward to working with them to develop integrations to our technology platforms for genotyping and gene expression applications."

?I am very excited about our partnership with Illumina. We are looking forward to offering Geneus with integrations to their BeadArray analysis software, BeadStudio, which will enable our customers with gene expression and genotyping applications to tie their data together using one integrating LIMS system. We will work closely with Illumina to ensure we develop seamless integrations that provide end-to-end solutions for researchers using Illumina genomics software and technologies,? said Jason Wilson, Product Manager at GenoLogics.

The most significant benefit from this partnership for customers ?this integration to Illumina software will enable customers to interconnect the Illumina technologies i n their lab with a LIMS and data management system developed specifically to address gene expression and genotyping workflows and genomics applications. This will allow for smooth data flow from one system to another with an integrating LIMS system that acts as the informatics backbone in one or multiple labs.

GenoLogics CEO, Michael Ball adds, "Our partnership with Illumina extends our network of strategic partners, building on one of our core differentiators. Our strong ties with best-in-class vendors enable us to provide end-to-end solutions for applications such as translational medicine and systems biology."

GenoLogics' Geneus provides LIMS functionality specifically for gene expression and genotyping applications and integrates to a wide variety of genomics instruments and software from best-in-class vendors, such as Illumina.

About GenoLogics

GenoLogics is the leading provider of bioinformatics software solutions that help life science laboratories specializing in the field of proteomics, genomics, and systems biology research to manage, integrate, and analyze enormous volumes of scientific and lab data. The Company's mission is to catalyze life sciences research with a collaborative data management software platform, advancing the early detection, prevention, and treatment of disease. For more information, please visit

About Illumina

Illumina, Inc. (NASDAQ: ILMN) is a leading developer, manufacturer, and marketer of next-generation life science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutic al companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients. For more information, please visit


Contact info:

GenoLogics Life Sciences Software, Inc. Tanis MacSween Manager, Marketing Communications 250.483.7063

Maurissa Bornstein, Public Relations Manager Illumina, Inc. Ph: 858.332.5055 Email:


Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:11/27/2015)... Research and Markets ( ) has announced the ... report to their offering. ... author the present scenario and growth prospects of the ... market size, the report considers revenue generated from the ... copper IUDs. The report forecasts the global intrauterine devices ...
(Date:11/26/2015)... November 26, 2015 Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Research . --> Clinical Cancer Research . ...
(Date:11/26/2015)... , Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met ... kanker. ) ...      (Photo: ) ... Leids Universitair Medisch Centrum (LUMC) ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... 29, 2015 , ... "I struggled for years with pain every day. I ... would love to do, I missed. We moved back home from living out of ... first. They have changed my life drastically. I love all of the people involved ...
(Date:11/29/2015)... ... , ... NewsWatch featured X-wing as part of its monthly Tech Report, which ... expert and special reporter for NewsWatch, conducted the review and shared with viewers how ... future because flying cars are about to become a reality. Where’s the idea from? ...
(Date:11/29/2015)... ... ... While conventional walkers afford considerable help with mobility, their design does not allow ... from Uniontown, Pa., has found a way to address those needs. , He developed ... to improve the user’s quality of life. To begin with, this improved mobility aid ...
(Date:11/29/2015)... ... November 29, 2015 , ... ProStatic ... distortion effect tool designed specially for Final Cut Pro X. FCPX ... with the easy-to-use modification controls. Destoying and creating chaotic distortion is now quick ...
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated ... announce their December, 2015, featured apartment community: Epic. In showcasing this featured apartment community ... the tight Bay Area rental market to efficiently find housing suitable to their needs ...
Breaking Medicine News(10 mins):